EKF Diagnostics Exhibits New POC Testing Technology at Arab Health

Cardiff, UK – 7th January 2014 –EKF Diagnostics, the global in vitro diagnostics business, will be exhibiting two newly introduced point-of-care (POC) testing analyzers for rapid assessment of diabetes and related conditions. The Quo-Lab glycated haemoglobin (HbA1c) analyzer and [5]STAT-Site M ß-HB will both be demonstrated on the Welsh Assembly Government Stand Z1D30 in Zabeel Hall 1, Arab Health, Dubai International Convention & Exhibition Centre, 27 - 30 January 2014.

Although only launched in July 2012, close to 1,300 Quo-Lab HbA1c analyzers were sold globally in 2013, 60 of which are now installed in Lebanon for near-patient measurement and monitoring of diabetes. HbA1c monitoring is increasingly used in the detection and management of diabetes and the Quo-Lab provides highly accurate, affordable and easy-to-use technology, which uses just 4 µL of venous or finger prick blood to deliver lab-accurate results within four minutes.

Small and lightweight, Quo-Lab is designed specifically to meet the needs of clinics and laboratories in emerging economies, where diabetes is an increasingly large public health issue, and is ideal for GP surgeries, diabetes clinics and laboratories.

EKF’s new STAT-Site M ß-HB will also be available for demonstrations. This new quantitative strip-based test for ß-Hydroxybutyrate (ß-HB) is CE marked and provides a quick and easy assessment of diabetic ketoacidosis (DKA), delivering results in less than 80 seconds.

Using the STAT-Site M ß-HB, the presence and degree of ketosis can be rapidly assessed at the point-of-care by accurately measuring blood levels of ß-HB, which accounts for 78% of the three ketone bodies, from just 10 µL of serum or plasma. This provides useful information to provide quality care when monitoring DKA in newly diagnosed patients, whilst also reducing time and costs in an emergency room setting .

Reference:

1) M. Vanelli, G. Chiari, C. Capuano, B. Iovane, A. Bernardini, T. Giacalone. PubMed - October 2003.

About EKF Diagnostics - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new Molecular division focuses on molecular and companion diagnostics.

Point-of-care diagnostics: EKF Diagnostics’ expertise covers the entire in vitro diagnostics chain, from fermentation and enzyme production, to liquid reagent manufacture, design and building of world-class diagnostic devices, and distribution of rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.

Companion Diagnostics: In March 2013 EKF set up a new division to focus on molecular and companion diagnostics - EKF Molecular Diagnostics develops technologies for cancer gene detection. Through its acquisition of UK-based 360 Genomics and by offering innovative products with the potential to change current DNA extraction and detection practices, EKF is addressing the fast growing companion diagnostics market.

EKF Diagnostics products are sold in more than 100 countries around the globe. EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.

  • <<
  • >>